Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | ILK | Q13418 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HTT | P42858 | 6/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10333750 | 0.88 | PDE3B (0.54) | NCF1ILKKDM4EALDH1A1POLB | |
| SCHEMBL10334199 | 0.84 | NCF1 (0.47) | NCF1KDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL10333474 | 0.84 | ALDH1A1 (0.51) | NCF1KDM4EALDH1A1HTTGAA | |
| SCHEMBL10333403 | 0.78 | PDE3B (0.51) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL10333628 | 0.76 | ILK (0.42) | ILKKDM4EALDH1A1HTTGAA | |
| SCHEMBL10333619 | 0.74 | GAA (0.57) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL7257484 | 0.72 | KDM4E (0.46) | ILKKDM4EALDH1A1HTTGAA | |
| SCHEMBL25366182 | 0.72 | GAA (0.58) | ILKKDM4EALDH1A1GAAHPGD | |
| SCHEMBL17942871 | 0.72 | NCF1 (0.54) | NCF1KDM4EALDH1A1L3MBTL1GFER | |
| SCHEMBL4037617 | 0.72 | NCF1 (0.54) | NCF1KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | UNIVERSITY OF VIRGINIA | 2008-12-25 | — | — | US | claimed |
| WO-2005076861-A2 | COMPOUNDS THAT INHIBIT HIV PARTICLE FORMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-4920128-A | TREATMENT OF HERPES VIRUS | STERLING DRUG INC. (US) | 1990-04-24 | — | — | US | claimed |
| US-20110152301-A1 | Compounds that Inhibit HIV Particle Formation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152301-A1 | Compounds that Inhibit HIV Particle Formation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-23 | — | — | US | disclosed |
| US-7875604-B2 | using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875604-B2 | using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875604-B2 | using 3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | UNIVERSITY OF VIRGINIA | 2008-12-25 | — | — | US | disclosed |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | UNIVERSITY OF VIRGINIA | 2008-12-25 | — | — | US | disclosed |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | UNIVERSITY OF VIRGINIA | 2008-12-25 | — | — | US | disclosed |
| WO-2005076861-A2 | COMPOUNDS THAT INHIBIT HIV PARTICLE FORMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-4920128-A | TREATMENT OF HERPES VIRUS | STERLING DRUG INC. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152301-A1 | Compounds that Inhibit HIV Particle Formation | REV1, VPS51, FLOT1 | NCF1 590/4885ILK 3257/4885KDM4E 3600/4885 |
| US-20080318959-A1 | Compounds that Inhibit Hiv Particle Formation | REV1, VPS51, FLOT1 | NCF1 590/4885ILK 3257/4885KDM4E 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.